ABBVIE INC

NYSE: ABBV (AbbVie Inc.)

最近更新时间: 2天之前, 1:22AM

225.64

2.63 (1.18%)

  • 1天 1.18%
  • 5天 2.21%
  • 1月 2.48%
  • 6月 13.64%
  • 今年至今天 -1.60%
  • 1年 17.67%
  • 5年 107.52%
前收盘价格 223.01
收盘价格 224.85
成交量 5,387,226
平均成交量 (3个月) 6,148,618
市值 398,792,654,848
市盈率 (P/E TTM) 169.65
预期市盈率 (P/E Forward) 15.70
价格/销量 (P/S) 6.55
股市价格/股市净资产 (P/B) 50.46
52周波幅
164.39 (-27%) — 244.81 (8%)
利润日期 4 Feb 2026
股息率 (DY TTM) 0.73%
营业毛利率 7.31%
营业利益率 (TTM) 30.43%
稀释每股收益 (EPS TTM) 2.35
季度收入增长率 (YOY) 8.40%
季度盈利增长率 (YOY) -6.10%
总债务/股东权益 (D/E MRQ) 4,789.60%
流动比率 (MRQ) 0.760
营业现金流 (OCF TTM) 16.40 B
杠杆自由现金流 (LFCF TTM) 16.94 B
资产报酬率 (ROA TTM) 8.34%
股东权益报酬率 (ROE TTM) 88.40%

市场趋势

短期 中期
行业 Drug Manufacturers - General (US) 看涨 混合的
Drug Manufacturers - General (全球的) 看涨 混合的
股票 AbbVie Inc. 看跌 看涨

AIStockmoo 评分

-0.4
分析师共识 1.0
内部交易活动 NA
价格波动 -0.5
技术平均移动指标 0.0
技术振荡指标 -2.0
平均 -0.38

相关股票

股票 市值 DY P/E（TTM） P/B
ABBV 399 B 0.73% 169.65 50.46
JNJ 573 B 0.52% 21.58 7.08
MRK 270 B 0.75% 14.29 5.55
PFE 151 B 1.62% 19.48 1.58
BMY 113 B 4.84% 18.71 6.14
GSK 108 B 1.62% 14.65 4.53

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
部门 Healthcare
行业 Drug Manufacturers - General
投资方式 Large Value
内部持股比例 0.10%
机构持股比例 74.87%
52周波幅
164.39 (-27%) — 244.81 (8%)
目标价格波幅
228.00 (1%) — 289.00 (28%)
高 289.00 (Piper Sandler, 28.08%) 购买
中 247.50 (9.69%)
低 228.00 (Evercore ISI Group, 1.05%) 购买
平均值 252.00 (11.68%)
总计 4 购买, 2 保留
平均价格@调整类型 223.80
公司 日期 目标价格 调整类型 价格@调整类型
Evercore ISI Group 05 Feb 2026 228.00 (1.05%) 购买 225.64
Morgan Stanley 05 Feb 2026 270.00 (19.66%) 购买 225.64
12 Dec 2025 269.00 (19.22%) 购买 223.32
UBS 05 Feb 2026 230.00 (1.93%) 保留 225.64
07 Jan 2026 240.00 (6.36%) 保留 233.42
Citigroup 27 Jan 2026 230.00 (1.93%) 保留 223.93
HSBC 10 Dec 2025 265.00 (17.44%) 购买 225.18
Piper Sandler 05 Nov 2025 289.00 (28.08%) 购买 216.77

该时间范围内无数据。

  • 3M
日期 类型 细节
30 Jan 2026 公告 $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium
29 Jan 2026 公告 AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships
28 Jan 2026 公告 Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine
16 Jan 2026 公告 AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
12 Jan 2026 公告 AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans
12 Jan 2026 公告 AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors
12 Jan 2026 公告 West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie
12 Jan 2026 公告 AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States
07 Jan 2026 公告 AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call
05 Jan 2026 公告 AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference
19 Dec 2025 CNBC Nine of the largest pharma companies ink deals with Trump to lower drug prices
14 Dec 2025 TheFinance 3 US Dividend Stocks Every Singapore Investor Should Know
02 Dec 2025 公告 AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
28 Nov 2025 公告 SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance
25 Nov 2025 公告 AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec
24 Nov 2025 公告 AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference
18 Nov 2025 公告 AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
14 Nov 2025 公告 AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer
13 Nov 2025 公告 AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™
12 Nov 2025 公告 Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence
06 Nov 2025 CNBC Eli Lilly to start late-stage trials on amylin obesity drug after it shows up to 20% weight loss in study 
显示更多
股息率 (DY TTM) 0.73%
5年平均股息收益率 3.22%
股息支付比率 268.80%
预计下次股息支付 May 2026
除息日 公告日期 支付日期 详情
15 Apr 2025 13 Feb 2025 15 May 2025 1.64 现金
15 Jan 2025 30 Oct 2024 14 Feb 2025 1.64 现金
15 Oct 2024 06 Sep 2024 15 Nov 2024 1.55 现金
15 Jul 2024 20 Jun 2024 15 Aug 2024 1.55 现金
12 Apr 2024 15 Feb 2024 15 May 2024 1.55 现金
12 Jan 2024 27 Oct 2023 15 Feb 2024 1.55 现金
12 Oct 2023 08 Sep 2023 15 Nov 2023 1.48 现金
13 Jul 2023 22 Jun 2023 15 Aug 2023 1.48 现金
13 Apr 2023 16 Feb 2023 15 May 2023 1.48 现金
12 Jan 2023 28 Oct 2022 15 Feb 2023 1.48 现金
13 Oct 2022 09 Sep 2022 15 Nov 2022 1.41 现金
14 Jul 2022 23 Jun 2022 15 Aug 2022 1.41 现金
13 Apr 2022 17 Feb 2022 16 May 2022 1.41 现金
13 Jan 2022 29 Oct 2021 15 Feb 2022 1.41 现金
14 Oct 2021 10 Sep 2021 15 Nov 2021 1.3 现金
14 Jul 2021 17 Jun 2021 16 Aug 2021 1.3 现金
14 Apr 2021 18 Feb 2021 14 May 2021 1.3 现金
14 Jan 2021 30 Oct 2020 16 Feb 2021 1.3 现金
14 Oct 2020 11 Sep 2020 16 Nov 2020 1.18 现金
14 Jul 2020 17 Jun 2020 14 Aug 2020 1.18 现金
14 Apr 2020 20 Feb 2020 15 May 2020 1.18 现金
14 Jan 2020 01 Nov 2019 14 Feb 2020 1.18 现金
11 Oct 2019 06 Sep 2019 15 Nov 2019 1.07 现金
12 Jul 2019 21 Jun 2019 15 Aug 2019 1.07 现金
12 Apr 2019 22 Feb 2019 15 May 2019 1.07 现金
14 Jan 2019 02 Nov 2018 15 Feb 2019 1.07 现金
12 Oct 2018 08 Sep 2018 15 Nov 2018 0.96 现金
12 Jul 2018 15 Jun 2018 15 Aug 2018 0.96 现金
12 Apr 2018 15 Feb 2018 15 May 2018 0.96 现金
11 Jan 2018 27 Oct 2017 15 Feb 2018 0.71 现金
12 Oct 2017 08 Sep 2017 15 Nov 2017 0.64 现金
12 Jul 2017 22 Jun 2017 15 Aug 2017 0.64 现金
11 Apr 2017 16 Feb 2017 15 May 2017 0.64 现金
11 Jan 2017 28 Oct 2016 15 Feb 2017 0.64 现金
12 Oct 2016 09 Sep 2016 15 Nov 2016 0.57 现金
13 Jul 2016 16 Jun 2016 15 Aug 2016 0.57 现金
13 Apr 2016 18 Feb 2016 16 May 2016 0.57 现金
13 Jan 2016 30 Oct 2015 16 Feb 2016 0.57 现金
13 Oct 2015 11 Sep 2015 16 Nov 2015 0.51 现金
13 Jul 2015 18 Jun 2015 14 Aug 2015 0.51 现金
13 Apr 2015 19 Feb 2015 15 May 2015 0.51 现金
13 Jan 2015 20 Oct 2014 13 Feb 2015 0.49 现金
10 Oct 2014 19 Sep 2014 17 Nov 2014 0.42 现金
11 Jul 2014 19 Jun 2014 15 Aug 2014 0.42 现金
11 Apr 2014 20 Feb 2014 15 May 2014 0.42 现金
13 Jan 2014 12 Dec 2013 14 Feb 2014 0.4 现金
10 Oct 2013 19 Sep 2013 15 Nov 2013 0.4 现金
11 Jul 2013 20 Jun 2013 15 Aug 2013 0.4 现金
11 Apr 2013 15 Feb 2013 15 May 2013 0.4 现金
11 Jan 2013 04 Jan 2013 15 Feb 2013 0.4 现金
显示更多

每年股息收益率

年份 每年总股息 ($) 频率/年份 收益率 %
2025 3.28 2 1.44
2024 6.20 4 3.49
2023 5.92 4 3.82
2022 5.64 4 3.49
2021 5.20 4 3.84
2020 4.72 4 4.41
2019 4.28 4 4.83
2018 3.59 4 3.89
2017 2.56 4 2.65
2016 2.28 4 3.64
2015 2.02 4 3.41
2014 1.66 4 2.54
2013 1.60 4 3.03
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明：以上内容仅供参考，并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票